未登录First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
Wicki, Andreas; Brown, Nicholas; Xyrafas, Alexandros; Bize, Vincent; Hawle, Hanne; Berardi, Simona; Cmiljanovic, Natasa; Cmiljanovic, Vladimir; Stumm, Michael; Dimitrijevic, Sasa; Herrmann, Richard; Pretre, Vincent; Ritschard, Reto; Tzankov, Alexandar; Hess, Viviane; Childs, Alexa; Hierro, Cinta; Rodon, Jordi; Hess, Dagmar; Joerger, Markus; von Moos, Roger; Sessa, Cristiana; Kristeleit, Rebecca .png)
分享.png)
收藏The Top 10 Adages in Continuous DeploymentParnin, Chris; Helms, Eric; Atlee, Chris; Boughton, Harley; Ghattas, Mark; Glover, Andy; Holman, James; Micco, John; Murphy, Brendan; Savor, Tony; Stumm, Michael; Whitaker, Shari; Williams, Laurie 分享 收藏 Final results of the pharmacodynamic (PD) data of PQR309-001 a first-in-human trial of a combined PI3K/mTOR inhibitor in advanced solid tumorsWicki, Andreas; Pretre, Vincent; Ritschard, Reto; Brown, Nicholas; Bize, Vincent; Fabbro, Thomas; Cmiljanovic, Natasa; Dimitrijevic, Sasa; Schmitz, Deborah; Stumm, Michael; Kristeleit, Rebecca 分享 收藏 分享 收藏 The Ret receptor tyrosine kinase pathway functionally interacts with the ERα pathway in breast cancerBoulay, Anne; Breuleux, Madlaina; Stephan, Christine; Fux, Caroline; Brisken, Cathrin; Fiche, Maryse; Wartmann, Markus; Stumm, Michael; Lane, Heidi A.; Hynes, Nancy E. 分享 收藏 分享 收藏 分享 收藏 分享 收藏 分享 收藏 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
